Smartpharm business development is identifying products that are attractive for our markets. After we perform the local IP status check, we position the products and provide an in-depth market analysis along with long-term volume and pricing forecast.

We have all typesof products in our portfolio - Rx, OTC, medical devices and food supplements. Smartpharm is not active in the segment of commodity generics. Instead, all products in our portfolio have one thing in common - they offer added value to patients on the markets that we cover. This added value can come in many forms: a molecule that is not present on a certain market yet, a new, improved formulation, more pleasant flavour, etc.

In composing our portfolio, we are ATC focused. Namely, many advantages of Smartpharm can be attributed to our lean organisational structure and only a carefully selected portfolio allows us to remain like that.

We are opened for all types of partnership - distribution under partner's brand name, licensing-in and development of our own brands or strategic partnerships to target certain market segments (e.g. tenders).